

IMMUNO

TRANSPLANTATION:

before blood transfusions: donor \neq recipient are matched for ABO \neq Rhesus D Ag

Blood Types:

O = universal DONOR
↳ can only receive O blood
they have anti-A \neq anti-B Ab

AB = universal RECIPIENT
↳ no anti-A or anti-B Ab

A = anti-B Ab
↳ only A or O blood

B = anti-A Ab
↳ only B or O blood

incompatibility of blood group antigens

↳ can cause TYPE 2 hypersensitivity *

↳ types of REJECTION:

can occur within minutes

hyperacute

* type 2 hypersensitivity *

↳ due to pre-existing Ab that attach graft

↳ causes: complement mediated lysis

* complete rejection can occur within 24 hours *

↳ ONLY treatment: graft removal

↳ avoid by typing \neq matching donor \neq recipient *

acute rejection:

responses between 7-10 days after transplant

↳ type 4 hypersensitivity

naive T cells are activated \rightarrow differentiate into effector cells
↳ induces infiltration of M+ \neq lymphocytes

↳ prevention: treat patients w/ immunosuppressive drugs before \rightarrow after transplant

chronic rejection

develops months/years after acute rejection reactions have subsided

↳ type 3 hypersensitivity

caused by IgG Ab made against HLA class I molecules in graft

↳ causes thickening of vessel walls \neq lumen narrowing = leads to ischemia, loss of function \neq eventual graft death

↳ anti-rejection drugs help, but are not perfect

due to indirect allorecognition

improve outcomes w/ transfusion effect

alloreactive T cells stimulated by direct pathway naive after transplant
↳ can give rise to reg. CD4 T cells to suppress alloreactive CD4 = CD8
↳ IMPROVES outcomes

* Graft terminology:

autograft = self-tissue grafted to another self area

isograft = transplant between identical individuals

allograft = tissue transferred between genetically different members of same species

xenograft = tissue transferred between different species

→ **type 4 hypersensitivity**

transplant rejection:

↳ Transplant of solid organ w/ alloreaction developed by individuals IS directed at graft cells

→ **type 4 hypersensitivity**

graft vs. host disease:

↳ after hematopoietic stem cell transplant

* donor attacks recipient *

* recipient's hematopoietic system is destroyed = gets healthy stem cells
 ↳ reaction due to donor T cells in graft that attack recipient's healthy tissues

↳ **Minimizing Rejection:**

* use donor whose HLA is as similar as possible

↳ ↓ autoreactive T cells

↳ Administer immunosuppressive drugs

↳ interfere w/ activation of alloreactive T cells

prednisone:

↳ prevents inflammation state

→ **Adverse effects:**

fluid retention
 weight gain
 diabetes
 loss of bone mineral
 skin thinning

Cyclosporin:

↳ inhibits T cell activation
 = disrupts signal transduction

→ **Adverse effects:**

nephrotoxicity

Tacrolimus:

↳ binds immunophilins

* **Serum sickness:**

extreme form of **type 3 hypersensitivity**

↳ occurs 7-10 days after administering therapeutic Ab
 = chills rash vasculitis
 fever arthritis glomerulonephritis

Blocking Alloreactive T Cells:

Belatacept → targets co-stim of T cells
 binds B7 on activated DC presenting alloantigens

Rapamycin (Sirolimus)

↳ binds Fc-binding proteins

Anti-CD25 Ab given before transplant
 ↳ 2 months after

↳ combo therapy

≈ Corticosteroid Therapy:	
ACTIVITY	EFFECT
↓ IL-1, TNF- α , GM-CSF ↓ IL-3, IL-4, IL-5, CXCL8	↓ inflammation caused by cytokines
↓ NOS	↓ NO
↓ Phospholipase A ↓ Cyclooxygenase type 2 ↑ Lipocortin-1	↓ Prostaglandins ↓ Leukotrienes
↓ adhesion molecules	reduced emigration of leukocytes from vessels
induction of endonucleases	induction of apoptosis in lymphocytes = eosinophils

Direct Allogeneic Recognition:

- ↳ donor DC presents to recipient T cells
- ↳ activated T cells destroy tissue

★ leads to ACUTE rejection ★

Indirect Allogeneic Recognition:

- ↳ donor DC not degraded by recipient DC
- ↳ recipient DC present to donor
- ★ activated T cells will attack graft ★

★ leads to CHRONIC rejection ★

STEM CELL THERAPY:

- ↳ choice of therapy for many genetic / malignant diseases
- within 2-3 weeks after transplant → new circulating blood cells begin to produce from transplant marrow

GVHD

→ can attack every tissue of body but usually: skin, intestine, liver

★ GVHD = type 4 hypersensitivity ★

- ↳ mature donor CD4+ CD8+ T cells respond to recipient HLA allotypes

4 grades:

★ begins 10-28 days after transplant ★

- ↳ creates inflammation

★ usually restricted to first few months after transplant ★

- ↳ ↑ liver enzymes
- cramps, diarrhea
- hyperbilirubinemia

★ All patients getting stem cell transfer will have GVHD ★

severity depends on HLA match

GRADES OF REJECTION:

Grade 1:	maculopapular rash <25% surface area	>500 ml diarrhea
Grade 2:	serum bilirubin 2-3 mg/dL maculopapular rash <25-50%	>1000 ml diarrhea
Grade 3:	serum bilirubin 3-10 mg/dL generalized erythroedema	>1500 ml diarrhea
Grade 4:	serum bilirubin 10-15 mg/dL generalized erythroedema w/ blistering & desquamation	Severe abd. pain w/ or w/out intestinal obstruction
	serum bilirubin 15 mg/dL	

- ↳ HLA matching: bone marrow is huge source of HSC

- using Ab specific for CD34 to extract stem cells
- ↳ could also use umbilical cord blood from placenta

★ ★ Graft vs. Leukemia Effect:

Alloreactive T cells in graft get rid of patient's residual leukemia cells

- ↳ after receiving stem cell graft: give patient transfusion of donor lymphocytes or T cells

- ↳ haploidentical transplant:

donor ≠ recipient share at least 1 HLA type

- deplete graft of T cells : give recipient anti-T cell Abs

- NK cells will reduce incidence of leukemia relapse

Disrupting Healthy Tissue:

tolerance:

Central:

↳ deletion of lymphocytes before they mature

* takes place in 1° lymph tissues *

↳ limits autoreactive T & B cells

* B cells can receptor edit *

dependent mechanism:

↳ occurs as TREG cells express ↑ levels of inhibitory CTLA-4

↳ bystander suppression:

or linked suppression = Tregs that interact w/ APC can suppress T cells that engage separate Ag-MHC class 2 on APC

Peripheral:

↳ either renders self-reactive lymphocytes non responsive or actively generates inhibiting lymphocytes

* occurs outside 1° lymph tissues (outside bone marrow = thymus)

↳ regulates autoreactive cells in circulation

regulatory CD4+ T cells

↳ can be generated in the thymus or in periphery
↳ nTREG ↳ iTREG

independent mechanism:

↳ rely upon secretion of cytokines to shut down nearby cell responses

regulatory CD8+ T cells:

* not generated in thymus but in periphery during CD8+ T cell activation induction events

appear after Ag-MHC class I stimulation

↳ use a range of mechanisms:

- * APC lysis
- * inhibition of APC function
- * regulates effector cell that bind same Ag

regulatory B cells:

may exist → produce IL-10 to inhibit adaptive immunity

MDSCs:

can secrete inhibition compounds to negatively regulate autoimmunity

AUTOIMMUNE DISEASES:

all resemble type 1, 2, 3, or 4 hypersensitivities

* due to failure of tolerance *

chronic diseases in which adaptive immune responses become misdirected

* Autoimmune hemolytic anemia:

↳ targets RBC

→ IgM & IgG bind components on RBC = activated complement

↳ lysis of RBC (leads to ANEMIA)
↳ ○○○

* signs & symptoms:

↳ pale skin
fatiguedness
dizziness
tachycardia

★ Neutropenia:

deficiency of neutrophils → see ↑ risk of infection

★ complement fixation leads to opsonization
↳ spleen removes & destroys opsonized

↳ WBC are less susceptible to complement mediated lysis than RBC

= ONLY treatment is splenectomy

★ Goodpasture's syndrome:

↳ AutoAb for α3 chain of type 4 collagen in basement membranes
IgG is deposited along basement membranes of organs

↳ esp. glomeruli & tubules & causes inflammation

↳ kidney function is impaired leading to failure & maybe death

↳ treatment: plasma exchange to get rid of Abs & immunosuppressive

Signs & symptoms:


↳ anemia
chest pain
bleeding from nose & urine
respiratory problems

★ systemic lupus erythematosus (SLE):

→ type 3 hypersensitivity

IgG is made against cell-surface & intracellular self-Ag

↳ in kidney = glomerulonephritis
joints = arthritis



Signs & symptoms:

↳ ↑ risk of CVD
anemia
fatigue
joint pain
fever/diarrhea
confusion
skin lesions/rashes

★ Multiple sclerosis:

→ type 4 hypersensitivity

autoimmune effector cells attach myelin sheath of nerve cells

onset: between 25 & 35 yrs. old
↳ death can occur within a year w/ severe cases

★ symptoms:

↳ muscle weakness
impaired vision
lack of coordination
spasticity (muscle contrac.)

↳ causes permanent damage & nerve deterioration

★ motility: gait issues

↳ progression can be SLOW or alternate between acute attacks & gradual recovery

↳ Activated TH1 cells activate M1 to release proteases

↳ causes plaque formation & demyelination

to treat:

↳ injection of IFN-β1 to reduce attack incidence & immunosuppressive drugs

* APPECED:

lack of **PIRE**

↳ common in Finns

without PIRE:
can't get rid of Ag that are autoreactive to self

* B = T cells are directed against tissues = endocrine glands

* persistent candida infections

↳ can lead to carcinoma or fulminant hepatitis

* IPEX:

↳ X-linked

↳ caused by: **FOXP3 mutation**

↳ master regulator for Tregs

immune dysregulation
polyendocrinopathy

enteropathy

MAINLY AFFECTS BOYS → (X-linked)

* no abn. at birth

↳ but develop enteritis w/ intractable diarrhea, type 1 diabetes, eczema within first months of life

* ↑ TH17 = eosinophils w/ ↑ IgE levels

* stem cell transplant to survive

* Ankylosing spondylitis:

↳ only one

more prevalent in **MEN**

* signs = symptoms: inflammation of joints in spine
↳ back pain
stiffness worsens w/ time

↳ onset between 20-30 yrs old

* treatment: medicine = exercise

* Graves' Disease:

chronic overproduction of T3 = T4 due to agonist Ab specific to TSH receptor = hyperthyroid

* other symptoms:

heat intolerance
nervousness

irritability
moist skin

weight loss
enlarged thyroid (goiter)

↳ bulging eyes (Ab binds eye muscles)

long-term → removal w/ surgery or irradiation

* Myasthenia Gravis:

↳ type 2 hypersensitivity

impaired signaling from nerve to muscle across nm junction

↳ autoAb bind Ach on muscles

↳ progressive muscle weakening

droopy eyelids

difficulty breathing (impaired chest muscles)

treat by inhibiting AChE

One line therapy

+ immunosupp. drugs

* Hashimoto's Thyroiditis

caused by TH1 response that makes Ab \Rightarrow CD4 T cells specific for thyroid Ag

\rightarrow destruction of tissues leads to hypothyroid

treatment = hormone replacement

* quiter due to inflammation \rightarrow massive IR

ECTOPIC LYMPH TISSUES:

seen in RA Graves' \Rightarrow MS

form in tissues that are chronically infected w/ pathogen \rightarrow (like liver during Hep C)

* Pemphigus vulgaris:

skin blistering

IgG Ab against desmoglein in cell junctions

interferes w/ integrity of skin

\rightarrow Ab made to EC5 = made 1st \Rightarrow don't cause immunopathology

\rightarrow Ab to EC1 = EC2 = immunopathology

* Rheumatoid Arthritis

\rightarrow type 3 hypersensitivity

\rightarrow onset between 20-40 yrs old

chronic = episodic joint inflammation

\rightarrow 80% of patients make IgM IgA } Ab for Fc region
IgG of IgG

\rightarrow immune complexes are deposited in tissues

\rightarrow treatment: anti-inflammatory AND immunosuppressive drugs

\rightarrow synovium is infiltrated w/ neutrophils M ϕ , CD4, CD8 B cells = plasma cells

* Type 1 diabetes:

\rightarrow type 4 sensitivity

T cell mediated

\rightarrow CD8⁺ T cells mediate destruction of beta cells \Rightarrow islets get infiltrated w/ lymphocytes

manifests early in childhood or adolescence

\rightarrow Islets of Langerhans: Alpha: glucagon
Beta: insulin
Delta: somatostatin

\rightarrow treat w/ synthetic insulin

* Celiac Disease

\rightarrow type 4 hypersensitivity

inflammatory disease of gut mucosa

\rightarrow inflammation becomes chronic w/ persistent gluten

gluten digested to: gliadin = glutenin

\rightarrow caused by IR to wheat flour or rye
CD4⁺ T cells respond to gluten peptides in GALT \Rightarrow activate tissue M ϕ

treat w/ removal of gluten

CANCER

abnormal = invasive cell proliferation

Median age = 70 yrs. old

due to several mutations

types of cancer:

★ Carcinoma:
most cancers → cancer of epithelial cells
↳ breast / prostate cancer

★ Sarcoma:
cancer of other cell types
↳ mesodermal CT → bone, fat = cartilage

★ Hodgkin's
↳ only B cells

★ Lymphoma:
cancer of solid lymph tumors
- cells within glands

★ Non-Hodgkin's
↳ T = B cells

★ Myeloma:
cancer involving bone marrow
- plasma cells

★ leukemia
★ lymphoma
★ myeloma } involving some part of immune sys.

Benign

walled off
DOES NOT spread

vs.

Malignant

continue to ↑ size =
invade other tissues

mode of spread → **metastasis**

metastasis: where cells are
carried by lymph
or blood to distant sites

Mutations → insertions / deletions
substitutions
recombinations

Gene classes:

proto-oncogenes
↳ contribute to normal cell division
↳ code for GF = proteins involved in signal trans. = gene trans.

↳ Ras
Her2
Myc

tumor suppressor
↳ normally code for proteins that prevent unwanted proliferation

↳ p53
Kb
Apc =
DCC

apoptotic genes:
↳ proapoptotic: act as tumor suppressors
↳ antiapoptotic: behave like oncogenes

↳ Bcl2: suppressor
Bim: inducer

★ need at least 5-6 independent mutations

Characteristics of Cancer Cells:

★ stimulate own growth
★ ignore growth-inhibiting signals

★ avoid death by apoptosis
★ develop blood supply
↳ angiogenesis

★ metastasis
★ replicate constantly

★ evade = outman IS

Immune responses to cancer:

innate inhibitors of cancer

★ Nk cells can target neoplastic cells
↳ mutations that ↓ Nk, ↑ certain cancers

★ activated Mφ bind Ab coated tumor cells =
secrete TNF

TILs
→ T cells } ↑ #
→ Nk cells } = better prognosis
→ NkT cells }

adaptive cell types involved in certain cancers

↳ each of T cells = ↑↑ cancer

★ B cells generate anti-tumor Ab against tumor specific Ag

TUMORS

cytokines = cancer:
TNF α :
 → may promote or inhibit anticancer effects
IL-12:
 → encourages DC to activate strong TH1 = CTL response
IFN γ :
 → All IFN enhance tumor cell removal

tumor specific Ag:
 not found on normal cells
 → just tumor cells
tumor associated Ag:
 found on certain normal cells = tumor cells
 → CT antigen:
 → MHC on germ cells



SUCCESSFUL TUMORS:


* can evade = manipulate IS
 * MHC is not found on healthy cells
 → expressed when cells are under **STRESS**

tumors have ↑ MHC
 → variant tumor created MHC soluble MHC binds NKGD2 on lymphocytes
 → cell is not killed = allows proliferation



* tumors can manipulate IS
 → Ag can be processed/presented by DC w/out B7
 → no activation bc no B7 to bind CD28 = cause signal

* tumors can also secrete TGF β = immunosupp. environment



VACCINATIONS:

HPV → links to anal mouth throat genital cancers
 w/ infections that last longer → infected cells integrate HPV DNA = express viral proteins

inactivates p53 = Rb = excessive replication → protein E5, 6, 7 contribute to malignant transfor.

* spread = incidence ↓↓

→ vaccination have NO EFFECT w/ ACTIVE infections

MONOCLONAL AB:

can boost T cell response

B2AF
 PD-1

* Multiple myeloma:

tumor of plasma cells that disrupts bone marrow

* treatments:

→ medications that block vessel formation
 immunosuppressant drugs
 inducers that cause tumor cell apoptosis